Rising demand for weight-loss medications is straining private employer health plans and triggering new federal pilot programs to manage high costs.
The fiscal reality of America’s weight-loss drug boom is coming into sharp focus as both private corporations and federal agencies grapple with the staggering price tags of GLP-1 medications. Bank of America CEO Brian Moynihan revealed on August 5, 2026, that the financial institution now spends more than $250 million annually on drugs like Ozempic and Wegovy for its employees. This figure represents a massive leap from virtually zero spending five years ago, now accounting for roughly one-eighth of the bank’s total $2 billion healthcare budget.
This corporate experience is a bellwether for the broader economy. Across the country, GLP-1 drugs have climbed to represent 11.4 percent of all employer health claims in 2026, up from 6.9 percent in 2023. With the average annual cost per user reaching approximately $6,540, eight in ten large employers report that these treatments are the primary driver of rising healthcare premiums. While 60 percent of employers currently restrict coverage to diabetes patients, the pressure to expand access for weight loss remains a significant point of contention. Currently, only 36 percent of employers cover the drugs for both diabetes and weight loss, a figure that has remained flat over the last year as companies balk at the long-term price tag.
The federal government is also moving to intervene. Despite a longstanding statutory ban on Medicare coverage for weight-loss drugs, the Centers for Medicare & Medicaid Services (CMS) has initiated a workaround using its demonstration authority. The Medicare GLP-1 Bridge demonstration, which launched on July 1, 2026, allows eligible Part D enrollees to access these drugs for obesity-related conditions at a fixed $50 monthly copay. Under this pilot, which runs through December 31, 2027, manufacturers have agreed to a net price of $245 per 30-day supply for the government. This is a stark contrast to domestic cash list prices, which for Ozempic and Wegovy range between $1,029 and $1,349 per month.
State Medicaid programs are also being restructured through the BALANCE Model. This model, which began a rolling rollout in May 2026, allows states to expand GLP-1 coverage through 2031. Participating state Medicaid agencies must sign formal agreements with CMS and enter into supplemental rebate negotiations with manufacturers. While these net prices remain confidential, the federal payment benchmark of $245 per month suggests a concerted effort by the administration to use the scale of public programs to force lower costs from pharmaceutical giants.
However, these government interventions highlight a growing disparity. While those in federal pilot programs or large corporate plans may see relief, other patients face a fragmented market. Licensed Tier-1 international pharmacies are currently sourcing the same molecules for between $190 and $375 per month, while domestic compounded versions have become increasingly restricted following the FDA’s delisting of the drugs from the official shortage list. This regulatory shift has limited the ability of smaller clinics to provide affordable alternatives, further consolidating the market in favor of major manufacturers.
As the FDA continues to monitor supply chains and the IRS implements new group tax exemption requirements for nonprofits under Rev. Proc. 2026-8, the administrative burden on the healthcare sector continues to grow. The current trajectory suggests that without greater price transparency and true market competition, the sacred doctor-patient relationship will increasingly be mediated by the fiscal constraints of corporate and federal payors. For the American worker, the promise of medical innovation is increasingly shadowed by the reality of a healthcare system struggling to balance access with an unsustainable bottom line.
Susan Carter serves as a Senior Correspondent for Just Right News, where she leads the network’s comprehensive coverage of Health, Medicine, and Public Policy. With a career dedicated to dissecting the complexities of the American healthcare system, Susan brings a principled perspective to the most pressing debates of the day. Her reporting is characterized by a commitment to individual liberty, fiscal responsibility, and a healthy skepticism of government overreach, making her a vital voice for audiences seeking clarity in an increasingly regulated landscape.
Raised in Minneapolis, Minnesota, Susan’s professional outlook is deeply informed by the values of the American heartland. Growing up in the Twin Cities, she witnessed firsthand the importance of community-driven solutions and the resilience of the individual. This Midwestern foundation instilled in her a firm belief that the best answers to public policy challenges often come from local innovation and personal responsibility rather than top-down federal mandates. Her background allows her to translate complex legislative jargon into stories that resonate with families who value common sense and local autonomy.
Now based in Baltimore, Maryland, Susan operates from a unique vantage point at the intersection of medical innovation and urban policy. Living and working in a city renowned for its world-class medical institutions and significant public health challenges, she has a front-row seat to the realities of the modern healthcare landscape. Her proximity to these hubs of research and policy allows her to scrutinize how government intervention affects the quality of care and the freedom of medical professionals. In Baltimore, she sees the tangible results of policy decisions, using the city as a lens through which to examine the broader national health debate and the impact of federal spending on local communities.
As the lead for the acclaimed feature series “The Cost of Care,” Susan dives deep into the economic realities facing patients and providers alike. Her work focuses on the necessity of price transparency, the benefits of market competition, and the preservation of the sacred doctor-patient relationship. She is a staunch advocate for the idea that a well-informed public is the best defense against bureaucratic inefficiency. Through this series, she has exposed the hidden drivers of rising medical expenses, always seeking to empower the individual consumer over the massive institution.
Susan’s reporting on public policy is characterized by a commitment to rigorous inquiry and a focus on constitutional limits. Whether she is analyzing new pharmaceutical regulations, investigating the impact of federal health mandates, or exploring the future of medical technology, her goal remains the same: to provide Just Right News audiences with the facts they need to navigate a complex world. By blending her Midwestern sensibilities with the insights gained from her base in Maryland, Susan Carter has become a trusted authority for those who believe that personal freedom and public health are inextricably linked. Her work continues to challenge the status quo, advocating for a system that respects the taxpayer and prioritizes the patient.